Halo Labs forms partnership with Agilent Technologies in Series C funding

 

BURLINGAME, CA – July 11, 2022 – Halo Labs, a leading life science instrumentation company announced it has raised $6M in series C financing. The round was led by Agilent Technologies Inc. and includes participation from existing investors Research Corporation Technologies, Broad Oak Capital Partners, BioAdvance, and members of the Board of Directors and senior management.

This new funding will be used for continued commercialization of Halo Labs’ Aura™ platform, increasing manufacturing capacity and developing innovative new products to meet the current and new needs of pharmaceutical researchers.

“For the past two years, Halo Labs has deployed an aggressive growth strategy and has raised the bar for innovation in our market,” said Rick Gordon, CEO of Halo Labs. “The fact that we were able to close on a funding round in the current economic environment demonstrates the success of that strategy. Our instruments have been adopted by virtually every major biopharmaceutical company and are now one of the leading tools in cell and gene therapy. With this capital, we will continue our current trajectory and scale our business in some exciting new directions. We are excited to have Agilent as a partner in that journey.”

First launched in 2017, Aura from Halo Labs has disrupted pharmaceutical product development by combining multiple stability, quality, and safety assays into one instrument. Now available in six different models, representing tools specific for different therapeutic modalities and development stages, Aura instruments give pharmaceutical scientists access to an unprecedented amount of data in a matter of minutes, allowing for new therapies to move from the lab to the clinic faster and more safely.

About Halo Labs

Halo Labs in Burlingame, CA is a venture-backed scientific instrumentation and consumable company that commercializes high throughput aggregate, visible and subvisible particle analysis for biopharmaceutical formulation, stability, and product quality control using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into aggregates and subvisible particles present in their drug products via optical imaging on membranes. For more information, visit www.halolabs.com.

About Agilent

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Agilent’s Early-Stage Partnerships program (ESP) works with startup companies to provide them with support and industry partnerships while providing strategic long-term value to Agilent. Information about Agilent is available at www.agilent.com.

Contact

Halo Labs
Steven Le
Director of Marketing
info@halolabs.com

###

Aura is a trademark of Halo Labs in the United States. All rights reserved.

Aura PTx™ analyzes degraded excipients in protein therapeutics, and Aura+™ is an all-in-one drug product quality tool for mAb, cell, and gene therapy

 

BURLINGAME, CA – January 17, 2022 – Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced that it has launched its latest products – Aura+ and Aura PTx.

Aura+ and Aura PTx are the next generation in Halo Labs’ popular family of instruments that combine Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM). Drug product researchers can easily and accurately detect excipient degradation for the first time in their therapeutics with Aura PTx. Aura+ is a comprehensive drug product quality solution for drug developers to ensure the safety, stability, and efficacy of their protein, cell, and gene therapies.

“Degraded excipients are a real problem for formulators because poor formulation leads to product instability and may compromise patient safety,” said Bernardo Cordovez, Ph.D., Chief Science Officer at Halo Labs. “Early identification and quantitation of degraded excipients such as polysorbate particles is critical for any therapeutic developer, so we developed a novel approach on Aura PTx to assess both excipient and protein stability and aggregation. Researchers can now truly understand the dynamic relationship between formulations and drug stability.”

“Developing best-in-class instruments that are highly focused on the needs of specific markets is what we do,” said Rick Gordon, CEO of Halo Labs. “Our customers have been asking for better solutions for product quality and CMC analytics, and we are consistently delivering. There is an Aura that fits your needs for those developing protein, cell, and gene therapies. Customers have also asked for products that span two or more therapeutic areas.  We’ve delivered on that request with Aura+.”

About Halo Labs

Halo Labs in Burlingame, CA is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation, stability, and product quality control tools for aggregate and subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Biopharmaceutical companies around the globe depend on Halo Labs for unprecedented insights into their drug products. For more information, visit www.halolabs.com.

Contact

Halo Labs

info@halolabs.com

###

Aura is a trademark of Halo Labs in the United States.  All rights reserved.

Aura GT is the first system specifically designed to quantify capsid aggregates and identify the mechanism of aggregation

 

BURLINGAME, CA – Oct 4, 2021 — Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT.

Aura GT is part of the next generation in Halo Labs’ popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy, Aura GT can distinguish aggregated capsids from contaminants, carrier proteins, and other particles that might adversely harm patients. Unique to Aura GT is the fact that it can also identify DNA leakage in gene therapy products so the mechanism of aggregation can be determined and corrected.

“Aura GT is going to completely revolutionize gene therapy product development. Gene therapy products are inherently unstable, which is a huge challenge. Up until now, there has been no effective way to correlate capsid aggregation with DNA leakage or empty and full capsids,” said Bernardo Cordovez, Chief Science Officer at Halo Labs. “In one assay, Aura GT can quantify capsid aggregates, distinguish them from protein aggregates, and determine if the aggregation is exacerbated by DNA leaking.”

“We are very excited to be launching our second instrument this year specifically developed for the cell and gene therapy market,” said Rick Gordon, CEO of Halo Labs. “Halo Labs has quickly become a leader in gene therapy analytics because we can answer many questions with very little volume. While other subvisible particle analyzers only do one thing, Aura systems offer a complete multi-assay platform that can be used to fully characterize gene therapy products from early development through lot release.”

About Halo Labs

Halo Labs in Burlingame, CA is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation, stability, and product quality control tools for aggregate and subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Biopharmaceutical companies around the globe depend on Halo Labs for unprecedented insights into their drug products. For more information, visit www.halolabs.com.

 

Contact

Halo Labs

Steven Le

Director of Marketing

info@halolabs.com

 

###

Aura is trademarks of Halo Labs in the United States.  All rights reserved.

Aura CL is the first system specifically designed to quantify cell aggregates and ID cell vs non-cell contaminants

 

BURLINGAME, CA – April 20, 2021 — Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, called the Aura CL.

The Aura CL is the next generation in Halo Labs’ popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy the Aura CL can distinguish therapeutic cells from contaminants and other particles that might adversely harm patients. It can count, size, and ID therapeutic cell types and determine if non-conforming particles are cellular, protein, or other types of material.

“The Aura CL is going to completely revolutionize cell therapy product quality analysis. Up until now, there has been no effective way to measure subvisible particles in cellular therapeutics because the drug product itself is also a particle,” said Bernardo Cordovez, Chief Science Officer at Halo Labs. “Other methods cannot distinguish cells from protein aggregates or even extrinsic particles that pose a danger to patients, but the Aura CL does it quickly and easily. In addition, the Aura CL has all the cytometric capabilities that cell therapy customers need. It can count cells, ID cell type, and measure viability all in one assay.”

“The cell and gene therapy market represent a unique opportunity for us because too many existing tools are not made in response to customer’s needs,” said Rick Gordon, CEO of Halo Labs. “There have been attempts to adapt older technology to these rapidly changing fields but there are still analytical gaps that haven’t been filled. I’m excited that Halo Labs can fill these voids to propel the industry forward, reduce development time, and improve patient safety.”

 

About Halo Labs

Halo Labs in Burlingame, CA is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation, stability, and product quality control tools for aggregate and subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Biopharmaceutical companies around the globe depend on Halo Labs for unprecedented insights into their drug products. For more information, visit www.halolabs.com.

 

 

Contact

Halo Labs
info@halolabs.com

 

###

Aura, Aura BMI, and Aura CL are trademarks of Halo Labs in the United States.  All rights reserved.

BURLINGAME, Calif., Nov. 23, 2020 /PRNewswire/ — Halo Labs, a life science instrumentation company developing tools for biologics researchers, announced today that Rick Gordon has been named Chief Executive Officer. He will assume day-to-day leadership of the Company and will also serve as a member of the Board of Directors.

Mr. Gordon has 20 years of experience in the life science tools market and has held senior positions at ForteBio, Phasefocus, and Unchained Labs. Most recently, he served as the Vice President of Global Sales for Halo labs where he oversaw both sales and customer support. He lead the commercial launch of their popular Horizon® and AuraTM instruments, built a global sales and distribution network, and expanded Halo Labs’ customer base to include virtually every major global biopharmaceutical company.

“Rick has a proven track record and is the right leader for Halo Labs,” said Dr. Joe Keegan, Executive Chairman of Halo Labs. “He understands our customers and with Rick’s strategic vision, the company is in a great position to execute on the market opportunities ahead.”

“Halo Labs is one of the most innovative companies in our industry and I’m excited about our future,” said Rick Gordon. “Thanks to the efforts of our team, our products have reduced therapeutic development timelines and have revolutionized stability testing across the industry. The Horizon and Aura systems have become the standard for high-throughput, low-volume particle analysis, and they are now considered the technology of choice in cell and gene therapy.”

About Halo Labs

Halo Labs in Burlingame, CA, is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation and quality control tools for subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into aggregates and subvisible particles present in their drug products via optical imaging on membranes. Halo Labs has been the recipient of many prestigious awards and research grants from agencies including DARPA, FDA, NSF, NIST, and NIH. For more information, visit www.halolabs.com.

 

Contact

Halo Labs
info@halolabs.com

 

 

###

 

###

Aura and Aura BMI are trademarks of Halo Labs in the United States.  All rights reserved.

Dr. Joseph Keegan, Executive Chairman, to Assume Interim Leadership

 

BURLINGAME, CA – October 16, 2020 — Halo Labs, a life science instrumentation company developing tools for biologics researchers, announced today it is releasing a non-fluorescence version of its revolutionary Aura™ platform.

This new instrument option known as the Aura BMI will improve on Halo Labs’ popular first-generation instrument, the Horizon®, which is being used by all of the world’s top biopharmaceutical companies to improve development timelines and patient safety. It adds improved optics for greater sensitivity, increased linear range, and the option to upgrade to fluorescence particle identification for full Fluorescence Membrane Microscopy. “When we launched the Aura platform in June, it instantly became popular with our customers” said Rick Gordon, Vice President of Sales at Halo Labs. “The low-volume particle identification feature of the Aura is something that many of our customers have been asking for because an easy solution to that problem has been lacking in the marketplace. At the same time, we also realize that simple and reliable particle counting remains a challenge for many labs because existing options do not demonstrate the assay linearity and reproducibility that they need for robust USP-level testing. The Aura BMI option delivers that for our customers with the ability to meet requirements of both low-volume and large-volume testing.”

Halo Labs also announced today that its CEO, Robert Wicke, has resigned his position with the company. Mr. Wicke remains a member of the Board of Directors but ceases to manage the day to day activity in the company. In Mr. Wicke’s place, Dr. Joseph Keegan, the Executive Chairman of Halo Labs, has assumed responsibility and is providing interim leadership. Halo Labs also stated that it is quickly working to identify a successor to Mr. Wicke.

“We thank Robert for his leadership over the past several years and wish him well” said Dr. Keegan, Executive Chairman of Halo Labs. “Robert recently oversaw the launch of the Aura, which allowed Halo Labs to become the leading provider of sub-visible particle analysis tools in the biologics and gene therapy markets. I look forward to the next phase of Halo Labs, and the company’s continued success.”

 

About Halo Labs

Halo Labs in Burlingame, CA, is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation and quality control tools for subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into aggregates and subvisible particles present in their drug products via optical imaging on membranes. Halo Labs has been the recipient of many prestigious awards and research grants from agencies including DARPA, FDA, NSF, NIST, and NIH. For more information, visit www.halolabs.com.

 

Contact

Halo Labs
info@halolabs.com

 

 

###

 

###

Aura is a trademark of Halo Labs in the United States.  All rights reserved.

Aura revolutionizes biologic stability analysis, enabling simple protein and non-protein aggregate identification in formulation development and analytical testing

 

BURLINGAME, CA – June 25, 2020 – Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.

Aura is the next generation of the Horizon®, Halo Labs’ popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range of over 3×106 particles/mL, BMI can count, size, and image aggregates and particles in the subvisible range (>1 μm). The Aura instrument now adds protein/non-protein identification using Fluorescence Membrane Microscopy (FMM) and is the only subvisible particle analyzer on the market to have 100% sample efficiency. An optional second fluorescence channel gives customers the ability to also detect lipids and other drug and process-specific particles.

“Aura is going to completely revolutionize biologic stability analysis,” said Rick Gordon, Vice President of Sales at Halo Labs. “Finally, there’s an easy way for our customers to identify if large aggregates in their samples are protein or non-protein without having to resort to slow and cumbersome methods like Raman and FTIR. Particle identification is critical to formulation development and analytical testing in all biologics because it defines the path that needs to be taken to mitigate problems. I’m extremely happy to be able to deliver this solution to our customers”.

“The wide adoption of our technology by every major biopharmaceutical company has given us a unique opportunity to listen to many customer voices,” said Robert Wicke, CEO of Halo Labs. “There is so much that this technology can offer and we are very excited to watch the Aura platform change the way stability and quality are analyzed in biologics.”

 

About Halo Labs

Halo Labs in Burlingame, CA, is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation and quality control tools for subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into aggregates and subvisible particles present in their drug products via optical imaging on membranes.  Halo Labs has been the recipient of many prestigious awards and has received many research grants from agencies including DARPA, FDA, NSF, NIST, and NIH. For more information, visit www.halolabs.com.

 

Contact

Halo Labs
info@halolabs.com

 

 

###

###

Aura is a trademark of Halo Labs in the United States.  All rights reserved.

 

BURLINGAME, Calif., April 6, 2020 /PRNewswire/ — Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has closed a $12M Series B1 financing round led by Research Corporation Technologies (RCT).  The funding will be used for expanding Halo Labs’ world-wide Sales presence and the continued development of the company’s next-generation product portfolio.  In addition, Halo Labs is actively looking at acquiring complementary technologies and companies to expand into the analytical particle space.

The Horizon® instrument performs high throughput subvisible particle (SVP) analysis using volumes as low as 25 µL, ensuring samples can be saved for other analyses or for replicates.  It has a 96-well membrane plate that allows several parameters to be tested in a short amount of time without dilution or sample preparation.

“Horizon is crucial at every stage of biologic drug formulation,” said Chad Souvignier, Vice President of RCT.  “In early stages, it can reveal SVP formation missed by other techniques such as light obscuration and flow imaging.  In later stages, it can differentiate proteins from extrinsic particles such as glass and plastic. And given the experience of the Halo Labs management team in product development and Sales, we are eager to find other technologies that we can help bring to market.” Additional backers included BroadOak Capital Partners, BioAdvance, top level industry executive Paul McEwan, and other current employees.

“The success of Horizon, especially in the Gene Therapy field, provides confirmation that next-generation product development is critical. There is so much more this technology can provide in a variety of markets,” said Robert Wicke, CEO of Halo Labs.  “One of our latest customers, the US FDA, will be using the product to help understand the risks for patients on drug product manufacturing. This is a further indication that Horizon is the product of choice for particle analysis in the subvisible range.

Halo Labs serves customers from the drug discovery phase through formulations and bioprocessing, empowering researchers to learn more about the stability and quality of their biological drugs faster and with more accuracy.  Over the years, Halo Labs has been the recipient of many prestigious awards and has received many research grants from agencies including DARPA, FDA, NSF, NIST, and NIH.

About Halo Labs
Halo Labs in Burlingame, CA, is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation and quality control tools for subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Researchers around the globe depend on Halo Labs for unprecedented insights into subvisible particles present in their processes via optical imaging on membranes.  For more information, visit www.halolabs.com.

About RCT
Research Corporation Technologies (RCT) in Tucson, Ariz., is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on investing in technology that originated in universities and research institutions worldwide. http://www.rctech.com

CONTACT
Halo Labs
info@halolabs.com

Horizon is a registered trademark of Halo Labs in the United States.  All rights reserved.

Company announces headquarters and all operations moving to San Francisco Bay Area

BURLINGAME, CALIFORNIA, May 1, 2019 — Halo Labs, a life science instrumentation company developing tools for subvisible particle analysis for biopharmaceuticals, today announced the opening of its new headquarters in Burlingame, California. The new headquarters will house sales, marketing, engineering, and manufacturing personnel and serve as the company’s primary Horizon® instrument production facility.  With the opening of its new headquarters, Halo Labs also announced its previous headquarters in Philadelphia will be closing by the end of fiscal Q2 2019.

Launched in 2017, the Horizon® system can analyze subvisible and visible particles, including protein aggregates.  Using the latest optics and innovative algorithms, it utilizes a plate-based approach that enables high-throughput (up to 96 samples/run), low-volume (as little as 25 µL/sample) particle analysis in a wide-range of pharmaceutical samples from pre-formulation through quality control for a wide range of therapeutics including biologics, vaccines, lipid nanoparticles, and small molecules.

“I am very excited to have Halo Labs right here at home in the San Francisco Bay Area.  The talent pool here is fantastic and our growth will be much faster here than anywhere else,” said Robert Wicke, CEO of Halo Labs.

About Halo Labs

Halo Labs is a venture-backed scientific instrumentation company that commercializes high-throughput biopharmaceutical quality control tools for particle analysis using the latest optics and image processing technologies.  Our core mission has been to provide researchers with unprecedented insights into the particles present in their processes by leveraging our core scientific competency: novel imaging optics and software. Today, we dedicate our collective experience and novel technology to empower formulation researchers to learn more about the stability and quality of their drugs faster and with more accuracy than ever before.  For more information, please visit www.halolabs.com

Contact
Halo Labs
info@halolabs.com